Pivotal study for PSD502 -- the first potential treatment for premature e... ( ATLANTA / SAN DIEGO (November 19 200...)

Pivotal study for PSD502 -- the first potential treatment for premature ejaculation

Date:11/19/2009

ATLANTA / SAN DIEGO (November 19, 2009) At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora" AIM:PLE)., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE). Results of the double-blind treatment phase of this study, which enrolled patients from the U.S., Canada and Poland, are consistent with previously reported results of the pivotal trial conducted in Europe and showed that men who were treated with PSD502 five minutes before intercourse were able to delay ejaculation up to five times longer than those who used placebo. Additionally, patients and partners in both trials reported significant improvements in sexual satisfaction, and the drug was well tolerated.

An estimated one-third of U.S. men ages 18 - 59 are affected by PE, making it twice as prevalent as erectile dysfunction. Currently, there are no prescription therapies approved in the U.S. to treat PE.

PSD502, a product in development for the treatment of PE, is a proprietary formulation of the two marketed drugs lidocaine and prilocaine dispensed by a metered dose aerosol. PSD502 works selectively on non-keratinized skin on the glans penis (head of the penis).

"Premature ejaculation can have a powerful negative impact on the emotional and sexual lives of men and their partners," said Professor Stanley E. Althof, PhD, Center for Marital and Sexual Health of South Florida, West Palm Beach, Florida. "Recently, the international sexual health community agreed that PE should be defined as ejaculation occurring within approximately one minute of penetration that causes the patient distress. Now we need to work to develop treatments, and these encouraging results with PSD502 seem to be a step in the right direction."

'/>"/>

Contact: Dave Schemelia
dschemelia@healthstarpr.com
609-468-9325
HealthStar PR
Source:Eurekalert

0

GOOD

Page: 1 2 3
Related medicine news :

1. Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
2. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
3. Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress
4. QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy
5. Pivotal White Paper Examines Retail Industrys Critical Role in Reengineering the Health Care System
6. Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization
7. Ambulatory Surgery Centers Pivotal in Moving Outpatient Surgical Services Into Less Expensive, Clinically Appropriate Settings
8. Medifocus, Inc. receives Authorization Approval from Health Canada to launch its pivotal Phase III clinical study of focused microwave heating for treatment of breast cancer in Canada
9. Pivotal Data on Bronchial Thermoplasty from the Asthma Intervention Research 2 (AIR2) Trial to be Presented at ATS 2009
10. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
11. Neuromed Announces Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial

Post Your Comments:

(Date:5/24/2013)... KC and Monica Craichy, Founders of Living Fuel, Inc ... Kyle and Austin Craichy, will be kiteboarding with members of ... , KC Craichy said he is excited to be involved ... that virtually everyone who planned to be involved is going ... meet at Matheson Hammock Park and Beach in Miami at ...

(Date:5/24/2013)... Mirena IUD lawyers at the Rottenstein Law Group ... more than 59,229 complaints since 2004 from women claiming they ... known as the Mirena IUD.* , Among the most common ... ‘expulsion,’ where the IUD came out on its own. There ... News article. “Abdominal pain is also common, with 3,774 complaints. ...

(Date:5/24/2013)... 2013 E-Dentists.com has announced the launch ... JD Media Surge, a leading medical Internet marketing agency. ... analysis service will focus on providing dentists the help ... for their competitive keywords. The dental SEO analysis covers ... based on what their competitors are doing right. The ...

(Date:5/24/2013)... OR (PRWEB) May 24, 2013 ... Sustainable Cards, major competitors in sustainable card material, ... of using forest materials as a sustainable gift ... is to identify industry challenges and increase education ... card programs to support the reduction of carbon ...

(Date:5/24/2013)... May 24, 2013 Started in 1982, AMTC’s ... in Orlando. 2013 marks AMTC’s 31st anniversary. SHINE is a ... with supermodel Millie Lewis and her daughter, Carey Lewis Arban. ... managers, casting directors, and music professionals including the New York ... XP Media. They are kings of Hollywood and Christian casting ...

Breaking Medicine News(10 mins):Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2 Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3 Health News:Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes 2 Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2 Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2 Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3 Health News:AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013 2

[0] FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa [0] Sufferers of Alleged Mirena IUD Side Effects Lodge More Than 59,000 Complaints With FDA, Rottenstein Law Group LLP Notes [0] Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge [0] Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants [0] AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013

... Japan to colloborate in marketing of Merck's cancer drug ... is in its Phase II // clinical tiral. ... royalty and sale benefits from the sale of Matuzumba. ... an addition of royalty., ,"Merck KGaA and Takeda ...

... (PET) brain scans may help in planning surgery to ... study presented at the 130th annual meeting of the ... from National Institutes of Neurological Disorders and Stroke had ... deficits in signaling for the neurotransmitter serotonin is more ...

... getting hospitals conscious about quality of services offered can reduce ... percent fewer patients died in the first year after their ... prevent crucial heart-care steps in much the same way a ... it leaves the factory., ,The steps included a checklist ...

... standards and strict hygienic conditions has to be monitored ... of hospital care and increase in number of hospitals ... should me monitored for the benefit of the ... facilities in Indian hospitals, there is an increase in ...

... Dr Reddy's Laboratories Thursday announced it had entered a ... the joint development of a drug to treat diabetes. ... fund all costs associated with the Phase-III clinical trials ... the treatment of type 2 diabetes., ,Dr Reddy's ...

... made by researchers at Wake Forest University School of Medicine said ... are quite high and it is also linked to the emphasis ... rates of musculoskeletal injuries. Almost half of workers reported pain in ... five of those workers was unable to work for at least ...

Cached Medicine News:Health News:Dr Reddy’s Strikes Deal With Rheoscience For Type 2 Diabetes Dru 2 Health News:Injury Rates High For Workers In Poultry Farms 2

Merck and Takeda to collaborate in the sale of Cancer drug Matuzumab PET scans may help deciding surgery for epilepsy Quality Awareness In Hospitals Can Reduce Mortality Rate Of Patients Indian hospitals require International Accreditation Dr Reddy’s Strikes Deal With Rheoscience For Type 2 Diabetes Dru Injury Rates High For Workers In Poultry Farms

(Date:5/24/2013)... -- In accordance with Rule 17.1 and Rule 2.9 of ... States Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today ... ELN). Background On 2 May 2013, ... the entire of the issued and to be issued share ... On 20 May 2013, Royalty Pharma announced the ...

(Date:5/23/2013)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ) today ... Science Firm of the Year by the Tech Council of ... the TCM,s 25 th Annual Tech Awards Celebration held ... Celebration recognizes the leaders and innovators in the technology and ... the surrounding regions. "We are deeply honored ...

(Date:5/23/2013)... RIVER EDGE, N.J. , May 23, 2013 /PRNewswire/ ... ), a commercial stage medical device company that develops ... the successful completion of its rights offering. In addition, ... company,s March 2011 warrants expired on May 17, 2013. ... proceeds of $3.0 million from the rights offering. A ...

Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9 Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2 Nephros Announces Completion of Rights Offering 2 Nephros Announces Completion of Rights Offering 3 Nephros Announces Completion of Rights Offering 4

[0] Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements [0] Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland [0] Nephros Announces Completion of Rights Offering

... and ATLANTA , March 15 ... announced results from an analysis of one-year subset data ... diabetes on clinical and angiographic outcomes in heart attack ... Stent System or the Express® bare-metal stent. The results ...

... Watson Pharmaceuticals, Inc. (NYSE: WPI ... – Florida , has received approval from the ... New Drug Application (ANDA) for Diltiazem Hydrochloride Extended-Release tablets, ... LA product. Watson intends to launch its generic version ...

Cached Medicine Technology:Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 2 Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 3 Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 4 Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 5 Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 6 Watson Receives FDA Approval for Generic Cardizem(R) LA 2 Watson Receives FDA Approval for Generic Cardizem(R) LA 3

Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack Watson Receives FDA Approval for Generic Cardizem(R) LA

... stereotactic, ultrasound and MRI-guided vacuum assisted breast ... Use the patented, FDA-cleared ATEC system for ... advanced method of breast biopsy. Its compassionate ... who trust YOU.,9 Gauge Handpieces: Useful for ...

Three-spring evacuator kits with silicone drains, 10 in. hole pattern, trocar and Y-connector tubing...

Provides reliable suction for surgical cases with larger amounts of drainage....

Medicine Products:

ATEC 9G Extra Long ATEC 9G Standard Three-spring evacuator kits with silicone drains, 10 in. hole pattern, trocar and Y-connector tubing Three-Spring 400cc Evacuators & Kits (Hemovac® Type)